These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 24967375)

  • 1. Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world.
    Salaffi F; Ciapetti A; Carotti M; Gasparini S; Gutierrez M
    Biomed Res Int; 2014; 2014():528105. PubMed ID: 24967375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
    Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
    J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender does not make a difference in "composite psoriatic disease activity index (CPDAI)" in patients with psoriatic arthritis.
    Kenar G; Yarkan H; Zengin B; Can G; Birlik M; Önen F
    Rheumatol Int; 2018 Nov; 38(11):2069-2076. PubMed ID: 30194455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disparity between ultrasound and clinical findings in psoriatic arthritis.
    Husic R; Gretler J; Felber A; Graninger WB; Duftner C; Hermann J; Dejaco C
    Ann Rheum Dis; 2014 Aug; 73(8):1529-36. PubMed ID: 23740228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of disease activity measures in early psoriatic arthritis in usual care.
    Wervers K; Luime JJ; Tchetverikov I; Gerards AH; Kok MR; Appels CWY; van der Graaff WL; van Groenendael JHLM; Korswagen LA; Veris-van Dieren JJ; Hazes JMW; Vis M;
    Rheumatology (Oxford); 2019 Dec; 58(12):2251-2259. PubMed ID: 31211399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity.
    Michelsen B; Diamantopoulos AP; Hammer HB; Soldal DM; Kavanaugh A; Haugeberg G
    Ann Rheum Dis; 2016 Dec; 75(12):2108-2113. PubMed ID: 27091837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
    Lubrano E; De Socio A; Perrotta FM
    J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission criteria and activity indices in psoriatic arthritis.
    Acosta Felquer ML; Ferreyra Garrott L; Marin J; Catay E; Scolnik M; Scaglioni V; Ruta S; Rosa J; Soriano ER
    Clin Rheumatol; 2014 Sep; 33(9):1323-30. PubMed ID: 24820142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Composite Measure Remission Targets in Psoriatic Arthritis.
    Farkas F; Ikumi N; Elmamoun M; Szentpetery A; FitzGerald O
    J Rheumatol; 2021 Aug; 48(8):1272-1278. PubMed ID: 33722944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.
    Helliwell PS; Deodhar A; Gottlieb AB; Boehncke WH; Xu XL; Xu S; Wang Y; Hsia EC; Gladman DD; Ritchlin CT
    Arthritis Care Res (Hoboken); 2020 Nov; 72(11):1579-1588. PubMed ID: 31421033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices.
    Lubrano E; Scriffignano S; Azuaga AB; Ramirez J; Cañete JD; Perrotta FM
    RMD Open; 2020 Mar; 6(1):. PubMed ID: 32179713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
    Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
    Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
    Helliwell P; Coates LC; FitzGerald O; Nash P; Soriano ER; Elaine Husni M; Hsu MA; Kanik KS; Hendrikx T; Wu J; Kudlacz E
    Arthritis Res Ther; 2018 Oct; 20(1):242. PubMed ID: 30373651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study.
    Coates LC; Nash P; Kvien TK; Gossec L; Mease PJ; Rasouliyan L; Pricop L; Jugl SM; Gandhi KK; Gaillez C; Smolen JS
    Semin Arthritis Rheum; 2020 Aug; 50(4):709-718. PubMed ID: 32521325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study.
    Sunar I; Ataman S; Nas K; Kilic E; Sargin B; Kasman SA; Alkan H; Sahin N; Cengiz G; Cuzdan N; Gezer IA; Keskin D; Mülkoğlu C; Resorlu H; Bal A; Duruöz MT; Küçükakkaş O; Yurdakul OV; Melikoglu MA; Aydın Y; Ayhan FF; Bodur H; Calis M; Capkın E; Devrimsel G; Gok K; Hizmetli S; Kamanlı A; Keskin Y; Kocabas H; Kutluk O; Şen N; Şendur OF; Tekeoğlu I; Tolu S; Toprak M; Tuncer T
    Rheumatol Int; 2020 Feb; 40(2):283-294. PubMed ID: 31773391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab.
    Helliwell PS; Kavanaugh A
    Arthritis Care Res (Hoboken); 2014 May; 66(5):749-56. PubMed ID: 24127416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual Disease Activity and Associated Factors in Psoriatic Arthritis.
    Lubrano E; Scriffignano S; Perrotta FM
    J Rheumatol; 2020 Oct; 47(10):1490-1495. PubMed ID: 31676704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of the Presence of Fibromyalgia on Common Clinical Disease Activity Indices in Patients with Psoriatic Arthritis: A Cross-sectional Study.
    Brikman S; Furer V; Wollman J; Borok S; Matz H; Polachek A; Elalouf O; Sharabi A; Kaufman I; Paran D; Elkayam O
    J Rheumatol; 2016 Sep; 43(9):1749-54. PubMed ID: 27252430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis.
    Wervers K; Vis M; Tchetveriko I; Gerards AH; Kok MR; Appels CWY; van der Graaff WL; van Groenendael JHLM; Korswagen LA; Veris-van Dieren JJ; Hazes JMW; Luime JJ
    Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1764-1770. PubMed ID: 29609220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
    Theander E; Husmark T; Alenius GM; Larsson PT; Teleman A; Geijer M; Lindqvist UR
    Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.